Richard Newmark

Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial

Jacques P. Brown, Richard L. Prince, Chad Deal et al. · Journal of Bone and Mineral Research · 2008 · 604 citations

Medicine, Pharmacotherapy, Bone Metabolism +16

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, phase II clinical trial

Stanley Cohen, Robin K. Dore, Nancy E. Lane et al. · Arthritis & Rheumatism · 2008 · 570 citations

Medicine, Pharmacology, Pharmacotherapy +17

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate

Mark C. Genovese, Stanley Cohen, Larry W. Moreland et al. · Arthritis & Rheumatism · 2004 · 522 citations

Medicine, Pharmacology, Pharmacotherapy +16

Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis

Philip J. Mease, Mark C. Genovese, Maria Greenwald et al. · New England Journal of Medicine · 2014 · 392 citations · Full text

Medicine, Immunology, Pharmacotherapy +16

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease

Stephan R. Targan, Brian G. Feagan, Séverine Vermeire et al. · The American Journal of Gastroenterology · 2016 · 372 citations

Veterinary Medicine, Immunology, Pharmacotherapy +16